In preparation for the fall, FDA advisors resoundingly recommended that a component of the Omicron variant be added to future vaccine doses. But just what that new vaccine formula looks like will be up to the agency to decide. We'll discuss how the committee came to its decision and what the future holds. But thats not all. Two reports – one from Moody’s and the other from PwC – discuss the outlook for mergers and acquisitions in the biopharma industry. Both reports point to an uptick in activity in both the short and long term. We'll discuss what the report says regarding financial flexibility and why the time is right for an increase in deals.

To learn more about the topics in this episode: 

The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. 

See omnystudio.com/listener for privacy information.